HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chambers, G. Articles by Nasir, L. Search for Related Content PubMed PubMed Citation Articles by Chambers, G. Articles by Nasir, L. Agricola Articles by Chambers, G. Articles by Nasir, L.

Association of bovine papillomavirus with the equine sarcoid

¹ Institute of Comparative Medicine, Department of Veterinary Pathology, University of Glasgow Veterinary School, Garscube Estate, Glasgow G61 1QH, UK
² Department of Veterinary Clinical Studies, University of Glasgow Veterinary School, Garscube Estate, Glasgow G61 1QH, UK

Correspondence
L. Nasir
l.nasir{at}vet.gla.ac.uk

The equine sarcoid, a locally aggressive, fibroblastic skin tumour, is the most common dermatological neoplasm reported in horses; there is no consistently effective therapy. It is widely accepted that bovine papillomavirus (BPV) types 1 and 2 are associated with the pathogenesis of sarcoid disease. Most sarcoids appear to contain detectable viral DNA and RNA and are also known to express the BPV types 1 and 2 major transforming protein, E5, but appear not to produce infectious virions. While the mode of transmission of infection has not been elucidated, viral gene expression, in particular of E5, may contribute to virus persistence and disease pathogenesis by downregulating MHC class I expression. Here, the pathology and epidemiology of the sarcoid and its association with BPV is reviewed; the transforming functions of the BPV oncoproteins and their possible role in sarcoid pathogenesis are discussed; and the practical implications of BPV infection for diagnostic and therapeutic purposes are considered.

Published ahead of print on 10 February 2003 as DOI 10.1099/vir.0.18947-0.

This article has been cited by other articles:

				G. Borzacchiello, S. Mogavero, G. De Vita, S. Roperto, L.D. Salda, and F. Roperto Activated Platelet-Derived Growth Factor {beta} Receptor Expression, PI3K-AKT Pathway Molecular Analysis, and Transforming Signals in Equine Sarcoids Vet. Pathol., July 1, 2009; 46(4): 589 - 597. [Abstract] [Full Text] [PDF]

				S. Roperto, R. Brun, F. Paolini, C. Urraro, V. Russo, G. Borzacchiello, U. Pagnini, C. Raso, C. Rizzo, F. Roperto, et al. Detection of bovine papillomavirus type 2 in the peripheral blood of cattle with urinary bladder tumours: possible biological role J. Gen. Virol., December 1, 2008; 89(12): 3027 - 3033. [Abstract] [Full Text] [PDF]

				N. Vasiljevic, K. Hazard, J. Dillner, and O. Forslund Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis J. Gen. Virol., October 1, 2008; 89(10): 2467 - 2474. [Abstract] [Full Text] [PDF]

				S. Brandt, R. Haralambus, A. Schoster, R. Kirnbauer, and C. Stanek Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines J. Gen. Virol., June 1, 2008; 89(6): 1390 - 1395. [Abstract] [Full Text] [PDF]

				S. Mattil-Fritz, D. Scharner, K. Piuko, N. Thones, L. Gissmann, H. Muller, and M. Muller Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles J. Gen. Virol., January 1, 2008; 89(1): 138 - 147. [Abstract] [Full Text] [PDF]

				M. Gottschling, A. Stamatakis, I. Nindl, E. Stockfleth, A. Alonso, and I. G. Bravo Multiple Evolutionary Mechanisms Drive Papillomavirus Diversification Mol. Biol. Evol., May 1, 2007; 24(5): 1242 - 1258. [Abstract] [Full Text] [PDF]